Conclusion
IPAF is a reasearch classification with no specific treatment due to its heterogeneity. Management should be discussed on a case-by-case basis in a pluri-disciplinary way. More studies should be done to achieve an effective therapeutic approach. Rituximab should be considered in patients with severe lung involvement.
Conflicts of Interests
The Authors declare that there are no competing interests.